Trial Profile
Ghrelin Suppression by Sandostatin LAR Depot (Octreotide Acetate for Injectable Suspension) in Patients With Prader-Willi Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Prader-Willi syndrome
- Focus Therapeutic Use
- 14 Dec 2022 Planned End Date changed from 1 Nov 2020 to 1 Nov 2024.
- 14 Dec 2022 Planned primary completion date changed from 1 Mar 2020 to 1 Mar 2024.
- 05 Aug 2019 Status changed to active, no longer recruiting.